GlobeNewswire Inc.··NaR1 Therapeutics Launches With $77.5M Series A to Develop First-in-Class Kidney Disease Treatment
R1 Therapeutics raised $77.5M in oversubscribed Series A funding to advance AP306, a first-in-class treatment for hyperphosphatemia in chronic kidney disease patients.
DVAclinical developmentdialysis